Subscribe for great stories in your community!
Conshohocken’s Madrigal Pharmaceuticals, saw third-quarter sales soar for its NASH treatment, Rezdiffra, writes John George for the Philadelphia Business Journal.
With revenue reaching…
Conshohocken-based Madrigal Pharmaceuticals generated $14.6 million in sales from Rezdiffra, its first and flagship product, during the second quarter of 2024, writes John…
In the less than two months since becoming the first drug developer to receive Food and Drug Administration clearance for a NASH treatment, Madrigal Pharmaceuticals…
Madrigal Pharmaceuticals has been given Food and Drug Administration market clearance for its experimental treatment for NASH, a fatty liver disease that causes inflammation of…
Later this week, the U.S. Food and Drug Administration is expected to make a decision on Madrigal Pharmaceuticals’ experimental NASH treatment, writes John George…
A Conshohocken-based pharmaceutical company’s treatment for nonalcoholic steatoheptatitis (NASH) a severe form of liver disease, is getting priority review by the Food &…
Conshohocken biopharmaceutical company Madrigal Pharmaceuticals has named Bill Sibold as the new CEO taking over from Dr. Paul Friedman.
He has also joined the company…
Before we send you to this site, please subscribe to our daily newsletter.
